A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.

Digestive Diseases and Sciences
Colleen SchmittB Hamelin

Abstract

To compare esomeprazole with omeprazole for healing erosive esophagitis (EE), 1148 patients with endoscopically confirmed EE were randomized to once-daily esomeprazole, 40 mg, or omeprazole, 20 mg, for 8 weeks in this multicenter, double-blind, parallel-group trial. The primary outcome was the proportion of patients with healed EE at week 8. Secondary outcomes included diary and investigator assessments of heartburn symptoms. At week 8, estimated healing rates were 92.2% (95% CI, 89.9%-94.5%) with esomeprazole and 89.8% (95% CI, 87.2%-92.4%) with omeprazole. Healing rates with esomeprazole were significantly higher than those with omeprazole at weeks 8 (88.4% vs 77.5%; P = 0.007) and 4 (60.8% vs 47.9%; P = 0.02) in patients with moderate to severe (Los Angeles grade C or D) EE at baseline but were not significantly different for patients with mild (Los Angeles grade A or B) EE. Both treatments were comparable for other secondary measures and had similar tolerability profiles.

References

Dec 1, 1995·Alimentary Pharmacology & Therapeutics·R CorinaldesiC Maier
Feb 2, 1999·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·A B ThomsonR H Hunt
Jul 28, 2001·Clinical Pharmacokinetics·T AnderssonL Weidolf
Feb 16, 2005·Alimentary Pharmacology & Therapeutics·M B FennertyM Sostek

❮ Previous
Next ❯

Citations

Aug 6, 2008·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Sep 4, 2013·Best Practice & Research. Clinical Gastroenterology·Philip WoodlandDaniel Sifrim
Sep 1, 2007·Current Treatment Options in Gastroenterology·Lucía C FryPeter Malfertheiner
May 1, 2009·Expert Review of Clinical Pharmacology·Alex Mejia, Walter K Kraft
Feb 13, 2009·Expert Review of Gastroenterology & Hepatology·Ravi VachhaniVic Velanovich
Jul 16, 2014·Expert Opinion on Drug Metabolism & Toxicology·Françoise GoirandMarc Bardou
Jul 18, 2009·Expert Opinion on Drug Metabolism & Toxicology·Consuelo L Saccar
Dec 4, 2010·Best Practice & Research. Clinical Gastroenterology·Stanislas Bruley des VarannesJean-Paul Galmiche
Mar 8, 2016·Journal of Comparative Effectiveness Research·Pawel PetryszynJedrzej Grzegrzolka
Jun 21, 2011·Alimentary Pharmacology & Therapeutics·P SharmaM Illueca
Feb 28, 2015·International Journal of Clinical Practice·J LabenzI Baldycheva
Jun 4, 2010·Arquivos De Gastroenterologia·Joaquim Prado P Moraes-FilhoUNKNOWN Brazilian Gerd Consensus Group
Jan 9, 2018·World Journal of Gastroenterology : WJG·Chih-Ming LiangUNKNOWN Taiwan Acid-Related Disease Study Group
Jun 5, 2007·Current Opinion in Gastroenterology·Emmanuel CoronJean-Paul Galmiche
Jun 19, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Lennart Estborn, Svante Joelson
Jan 12, 2010·European Journal of Gastroenterology & Hepatology·Mohammad YaghoobiRichard H Hunt
Mar 19, 2019·Journal of Gastroenterology and Hepatology·Hirota MiyazakiToshiro Tango
Feb 28, 2013·Journal of Clinical Gastroenterology·Prateek SharmaDebra G Silberg
Jun 22, 2013·Journal of Clinical Gastroenterology·Péter NagyAndreas Jonsson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.